Encenicline

Drug Profile

Encenicline

Alternative Names: Alpha-7 nAChR; EVP-6124; MT-4666

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer HealthCare
  • Developer Bayer HealthCare; FORUM Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation
  • Class 2 ring heterocyclic compounds; Amides; Azabicyclo compounds; Nootropics; Quinuclidines; Thiophenes
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease; Cognition disorders

Most Recent Events

  • 02 Aug 2016 Encenicline is no longer licensed to Mitsubishi Tanabe in Japan (Mitsubishi Tanabe pipeline, August 2016)
  • 02 Aug 2016 Discontinued - Phase-II for Alzheimer's disease in Japan (PO) (Mitsubishi Tanabe pipeline, August 2016)
  • 01 May 2016 FORUM terminates phase III trial in Cognition disorders (Adjunctive treatment) in USA, Canada, Mexico, United Kingdom, France, the Czech Republic, the Netherlands, Germany, Italy, Spain, South Korea, South Africa and Australia (NCT01969136)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top